Copyright ©2014 NPR. For personal, noncommercial use only. See Terms of Use. For other uses, prior permission required.

DAVID GREENE, HOST:

NPR's Business News begins with backing off of a big deal. Well, it would have been the biggest takeover the pharmaceutical industry had seen in over a decade, but for now it is off the table. Pfizer has withdrawn its offer to buy the British drug company AstraZeneca for about $119 billion, as NPR's Elizabeth Blair reports.

ELIZABETH BLAIR, BYLINE: The American pharmaceutical giant Pfizer, which makes Lipitor and Viagra, has been circling its smaller rival AstraZeneca for months. AstraZeneca, which makes Nexium and Crestor, has rejected every offer saying Pfizer undervalues the company and that it wants to remain independent.

There were fears that jobs and research facilities in the U.K. would be lost. Had the deal gone through, Pfizer could had reincorporated in Brighton and taken advantage of lower taxes. Inversions, as they're called, annoy members of Congress who say they erode the U.S. corporate tax base. Both companies face stiff competition in the future as more and more people turn to cheaper generic drugs. Elizabeth Blair, NPR News.

Copyright © 2014 NPR. All rights reserved. No quotes from the materials contained herein may be used in any media without attribution to NPR. This transcript is provided for personal, noncommercial use only, pursuant to our Terms of Use. Any other use requires NPR's prior permission. Visit our permissions page for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.